Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%GOLD$4,122.10+1.21%OIL$87.41-0.81%
Delayed
Smart Investors Daily
SID Premium
IM

NASDAQ · IMMP

Immutep Limited

Healthcare · Biotechnology

$3.00

Down-$0.05 (-1.50%)

Updated Nov 5, 2026, 1:31 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
388.59M
P/E ratio
-9.02
Dividend yield
0.00%
52-week range
$0.28 – $5.92
Volume
12.17K
Avg. volume
634.76K

Price performance · IMMP

IMMP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

IMMP closed at $3.00 after 20 trading sessions, down 26.23% for the selected period.

Last close
$3.00
Period change
-26.23%
Period low
$3.00
Period high
$4.06
Daily close
View OHLC price history
IMMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.03$3.12$2.985$2.99512.17K
Nov 2, 2026$3.10$3.1113$3.00$3.0711.63K
Oct 30, 2026$3.30$3.30$3.05$3.0610.59K
Oct 29, 2026$3.04$3.55$3.04$3.3314.04K
Oct 28, 2026$3.19$3.46$3.19$3.3229.53K
Oct 27, 2026$3.10$3.30$3.10$3.1513.56K
Oct 26, 2026$3.28$3.28$3.05$3.1027K
Oct 23, 2026$3.21$3.23$3.10$3.207.94K
Oct 22, 2026$3.27$3.27$3.0727$3.177.54K
Oct 21, 2026$3.22$3.395$3.21$3.289.21K
Oct 20, 2026$3.15$3.4195$3.15$3.2616.37K
Oct 19, 2026$3.29$3.29$3.13$3.176.78K
Oct 16, 2026$3.27$3.27$3.18$3.2011.87K
Oct 15, 2026$3.31$3.31$3.06$3.2119.07K
Oct 14, 2026$3.48$3.54$3.36$3.3838.7K
Oct 13, 2026$3.60$3.70$3.437$3.5727.01K
Oct 12, 2026$3.57$3.70$3.56$3.6718.62K
Oct 9, 2026$3.785$3.785$3.55$3.6323.41K
Oct 8, 2026$4.02$4.1036$3.80$3.8414.9K
Oct 7, 2026$4.28$4.31$4.04$4.069.61K

Latest IMMP news

The latest Smart Investors Daily articles mentioning IMMP.

Stock researchCompany · Overview

IMMP research

Overview

Company profile and research snapshot.

Company profile

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.25
Implied upside
—
Analysts
—
IMMP recent ratings
DateFirmRatingTarget
Sep 22, 2026BELL POTTER SECURITIESHold—
Sep 2, 2026JEFFERIESHold—
Mar 31, 2026BELL POTTER SECURITIESHold—
Mar 30, 2026BELL POTTER SECURITIESHold—
Mar 2, 2026JEFFERIESBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Immutep Receives A$2.16 million French R&D Tax Incentive

SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive program, for eligible R&D activities conducted in calendar year 2025. The CIR is a French Government inc

Yahoo · Oct 23, 2026

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life (HRQoL) data from the investigator-initiated EFTISARC-NEO Phase II trial. The data are

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By